What is Ribometrix?
Ribometrix is pioneering a novel drug discovery paradigm by developing small molecule therapeutics designed to interact with cellular RNAs. This innovative approach aims to correct the production of disease-causing proteins, addressing a broad spectrum of conditions. By integrating established drug discovery methodologies with cutting-edge RNA-targeting technologies, Ribometrix is positioned at the vanguard of a transformative field in medicine. The company actively engages in strategic collaborations to advance its mission of modulating RNA through small molecules, operating from its base in North Carolina's Research Triangle Park.
How much funding has Ribometrix raised?
Ribometrix has raised a total of $45.3M across 3 funding rounds:
Angel/Seed
$7.5M
Series A
$30M
Other Financing Round
$7.8M
Angel/Seed (2017): $7.5M with participation from SV Health Investors, Dementia Discovery Fund, MP Healthcare Venture Management, and Hatteras Venture Partners
Series A (2018): $30M led by M Ventures
Other Financing Round (2019): $7.8M supported by Illumina Ventures and Dementia Discovery Fund
Key Investors in Ribometrix
M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, focused on investing in innovative technologies with the potential to impact core business areas. They invest globally in transformational ideas and take an active role in their portfolio companies.
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on translating investment into innovation to enhance human health. They support companies advancing life science research and biopharmaceutical drug development.
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative health care and life science companies. They partner with founders to provide capital, sector expertise, and active support from early growth through scale.
What's next for Ribometrix?
With the recent influx of capital, Ribometrix is poised to accelerate its research and development initiatives, potentially advancing its pipeline of RNA-targeting therapeutics. The company's focus on small molecule approaches to RNA modulation suggests a strategic emphasis on creating orally available drugs, a significant advantage in the pharmaceutical market. Future endeavors will likely involve further clinical development, expansion of strategic partnerships, and continued innovation in identifying and validating novel RNA targets. This strategic investment provides the necessary runway for Ribometrix to solidify its position as a leader in RNA-based therapeutics.
See full Ribometrix company page
